What is the Concept of Sliding-Scale Insulin Infusion?
Sliding-scale insulin is a reactive, correction-only approach that treats hyperglycemia after it has already occurred, rather than preventing it—this method is strongly discouraged in hospitalized patients and should not be used as monotherapy. 1
Definition and Mechanism
Sliding-scale insulin refers to a traditional regimen where predetermined doses of short- or rapid-acting insulin are administered based on current blood glucose readings, without any basal (long-acting) insulin component. 1 The approach typically uses regular insulin administered at fixed intervals, with doses adjusted according to a pre-defined scale that correlates insulin units to specific glucose ranges. 1
Why Sliding-Scale is Problematic
The fundamental flaw of sliding-scale insulin is its reactive rather than proactive nature:
- It treats hyperglycemia retrospectively rather than preventing glucose elevations from occurring in the first place 1
- The prescribed regimen typically remains unchanged throughout hospitalization even when glycemic control remains poor, as clinicians often fail to modify the initial orders 1
- It causes rapid glucose fluctuations that can exacerbate both hyperglycemia and hypoglycemia through its "reactive" approach 1
- It has been proven ineffective as monotherapy in patients with established insulin requirements 1
Evidence Against Sliding-Scale Use
Clinical trials consistently demonstrate inferior outcomes with sliding-scale insulin compared to structured basal-bolus regimens:
- Only 38% of patients on sliding-scale insulin achieved glycemic control (mean blood glucose <140 mg/dL) compared to 68% with basal-bolus therapy 1
- Sliding-scale insulin is associated with clinically significant hyperglycemia in many patients 1
- The sole use of sliding-scale insulin in the inpatient hospital setting is strongly discouraged (Grade A recommendation) 1
Limited Appropriate Use
The only acceptable context for sliding-scale insulin is as correction-dose supplementation, not as primary therapy:
- It may be appropriate in patients without diabetes who have mild stress hyperglycemia 1
- It can serve as an adjunct to scheduled basal-bolus insulin for dose-finding and supplemental correction when rapid changes in insulin requirements occur 1
- It should never be used alone in patients with type 1 diabetes 1
Preferred Alternative: Basal-Bolus Approach
Instead of sliding-scale monotherapy, hospitalized patients should receive:
- Basal insulin (long-acting) given once or twice daily to provide continuous background insulin coverage 1
- Nutritional/prandial insulin (rapid-acting) given before meals to cover carbohydrate intake 1
- Correction-dose insulin (rapid-acting) as needed to address unexpected hyperglycemia 1
This structured approach reduces perioperative complications including wound infection, pneumonia, bacteremia, and acute renal and respiratory failure compared to sliding-scale insulin alone 1
Common Pitfall to Avoid
The most critical error is placing an order for sliding-scale insulin when transitioning from intravenous insulin infusion—this constitutes medical mismanagement and should be replaced with a basal-prandial-correction regimen before discontinuing the IV insulin. 2